No surprise: After near unanimous adcomm, FDA rejects Eli Lilly bid to bring Jardiance to type 1 patients
In an unsurprising move, the FDA has rebuffed Eli Lilly and Boehringer Ingelheim in their efforts to expand the indication for their best-selling diabetes drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
